MARGINAL ZONE LYMPHOMA

This study tested a drug called zanubrutinib for people with several types of B-cell lymphoma who had to stop their previous treatments due to bad side effects. The main goal was to see if zanubrutinib caused fewer or less severe side effects for these patients. Researchers also …

This early-stage study tested a new drug called PRT2527, both by itself and combined with other cancer drugs, in people with advanced blood cancers that had returned or stopped responding to standard treatments. The main goals were to find a safe dose and see if the treatments sh…

This early-phase study tested the safety and best dose of a new drug called BGB-10188. It was given alone or combined with other cancer drugs to 97 patients with advanced blood cancers or solid tumors that had returned or stopped responding to prior treatments. The main goal was …

This study tested whether a treatment called axicabtagene ciloleucel, a type of CAR-T cell therapy, could help people with slow-growing non-Hodgkin lymphoma that had come back or stopped responding to other treatments. It involved 159 participants whose cancer had progressed afte…

This study tested a new oral medication called pirtobrutinib for people with chronic lymphocytic leukemia or other B-cell lymphomas that had stopped responding to standard treatments. The main goals were to find a safe and effective dose and to see if the drug could shrink tumors…

This first-in-human study tested a new oral drug called BR101801 in adults with advanced blood cancers that had returned or stopped responding to other treatments. The main goals were to find a safe dose and see how the body processes the drug. Researchers also looked for early s…

This study tested the safety of swapping out one drug (cyclophosphamide) for another (bendamustine) in the days following a bone marrow transplant. It involved 50 patients with various blood cancers who needed a transplant but lacked a perfectly matched donor. The goal was to see…